19 completed, 3 terminated, 2 unknown, 1 recruiting. 7 Phase 4, 5 Phase 1, 5 Phase 2, 3 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 6, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Unknown 2 |
| Phase 2 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
| Not applicable | 2 | Completed 1, Terminated 1 |
Follow darifenacin: new trials by email Literature Review of darifenacin trials Research Report on darifenacin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS Darifenacin 7.5 MG Extended Release Oral Tablet, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Recruiting | Oliver Blanchard | 60 | 2024-11-08 | 2026-10-09 |
| Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS Tadalafil 5Mg Tab, Darifenacin 7.5 MG - Management of Ureteric Stent Related LUTS and Pain | Phase 1 / Phase 2 | Completed | Ain Shams University | 150 | 2022-05-01 | 2026-01-16 |
| Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1 Darifenacin, Neuromodulation - Sacral nerve stimulation - HTLV-1, Overactive Bladder Syndrome | Phase 4 | Completed | Hospital Universitário Professor Edgard Santos | 42 | 2022-03-16 | 2024-10-01 |
| Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 5589 | 2018-07-20 | 2024-10-16 | |
| A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB) | Completed | Astellas Pharma Singapore Pte. Ltd. | 805 | 2018-07-19 | 2020-04-22 | |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) mirabegron, antimuscarinic medication - Urinary Bladder Overactive, Overactive Bladder | Completed | Astellas Scientific & Medical Affairs, Inc. | 1524 | 2015-01-05 | 2024-10-16 | |
| Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women Darifenacin, Physiotherapy - Overactive Bladder | Phase 3 | Completed | Universidad de Valparaiso | 80 | 2014-05-01 | 2016-05-02 |
| Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-12-01 | 2010-10-27 |
| Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-11-01 | 2010-10-25 |
| Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness darifenacin, Placebo - Nocturia | Phase 4 | Withdrawn | Cognitive Research Corporation | 2009-11-01 | 2016-04-13 | |
| Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain Darifenacin - Overactive Bladder, Renal Colic | Not applicable | Terminated | University of Missouri-Columbia | 3 | 2009-08-01 | 2016-11-21 |
| Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease Oxybutynin and darifenacin - Parkinson's Disease, Overactive Bladder | Not applicable | Completed | US Department of Veterans Affairs | 12 | 2009-05-01 | 2014-10-03 |
| A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity Darifenacin - Neurogenic Detrusor Overactivity | Phase 2 | Terminated | Warner Chilcott | 35 | 2008-10-07 | 2022-06-09 |
| Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects Darifenacin, Tolterodine, Placebo - Healthy | Phase 1 | Completed | Novartis | 117 | 2008-05-01 | 2012-08-02 |
| Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Oxybutynin Cl, Trospium Cl, Darifenacin Hydrogen Bromide (HBr) - Spinal Cord Injury, Neurogenic Detrusor Overactivity | Phase 4 | Completed | Toronto Rehabilitation Institute | 23 | 2008-03-01 | 2013-04-08 |
| FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period Darifenacin (Emselex, BAY79-4998) - Overactive Bladder | Completed | Bayer | 9 | 2007-06-01 | 2015-04-20 | |
| Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity Darifenacin (BAY79-4998) - Multiple Sclerosis, Overactive Detrusor | Phase 2 | Terminated | Bayer | 7 | 2007-02-01 | 2014-12-02 |
| Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects Darifenacin, Tolterodine, Placebo - Healthy | Phase 4 | Completed | Novartis | 162 | 2006-11-01 | 2008-01-15 |
| Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Darifenacin - Overactive Bladder (OAB) | Phase 4 | Completed | Novartis | 500 | 2006-06-01 | 2008-01-15 |
| Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects Darifenacin (DAR328) - Healthy | Phase 1 | Completed | Novartis | 28 | 2006-06-01 | 2016-04-12 |
Showing 20 of 26. Sign in to see all of them.
Urinary Bladder, Overactive (18) · Spinal Cord Injuries (2) · Amyotrophic Lateral Sclerosis (1) · Kidney Calculi (1) · Meningomyelocele (1) · Multiple Sclerosis (1) · Nocturia (1) · Pain (1) · Pain, Postoperative (1) · Parkinson Disease (1) · Renal Colic (1) · Urinary Bladder Diseases (1) · Urinary Incontinence (1) · Urinary Incontinence, Urge (1) · Urologic Diseases (1)
Novartis (9) · Bayer (3) · Astellas Pharma Singapore Pte. Ltd. (2) · Center for Clinical Pharmacology Research Bdbeq S.A. (2) · Ain Shams University (1) · Astellas Scientific & Medical Affairs, Inc. (1) · Cognitive Research Corporation (1) · Hospital Universitário Professor Edgard Santos (1) · Oliver Blanchard (1) · Toronto Rehabilitation Institute (1) · US Department of Veterans Affairs (1) · Universidad de Valparaiso (1) · University of Missouri-Columbia (1) · Warner Chilcott (1)
United States (12) · Canada (3) · Germany (2) · South Korea (2) · Uruguay (2) · Australia (1) · Brazil (1) · Chile (1) · Colombia (1) · Egypt (1) · India (1) · South Africa (1) · Taiwan (1)
Francisco E. Estevez-Carrizo, MD (2) · Susana Parrillo, M.D. (2) · Herman Ellman, MD (1) · Jayne R Wilkinson, MD (1) · Magdy Hassouna, MD (1) · Mark R Wakefield, MD (1) · Melissa Cifuentes, M.D. (1) · Oliver Blanchard, MD (1)
PMID 18663723, PMID 18811599, PMID 20860020, PMID 26724409, PMID 29264126, PMID 29777865, PMID 31222714, PMID 34225282, PMID 37148497, PMID 37160401, PMID 37811598, PMID 38430402, PMID 41224659